Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBAR: Plasma Exchange with Albumin in Alzheimer's
NCT01561053Phase 3Completed
- Sponsor
- Grifols
- Start
- Apr 2012
- Primary completion
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of albumin (human) in Alzheimer's disease (AD) (4 arms), sponsored by Grifols. Primary endpoints: Alzheimer's Disease Assessment Scale - Cognitive Subscale at 14 months and Alzheimer's Disease Cooperative Study-Activities of Daily Living at 14 months. Started Apr 2012; status: completed.
02
Drugs
albumin (human)
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01561053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01561053.